Hansoh Pharmaceutical (03692.HK) Reports Interim Results with Shareholder Profit Soaring 111.47% Year-on-Year to RMB 2.726 Billion

Hansoh Pharma (03692) announced its financial results for the six months ended June 30, 2024. During this period, the group achieved revenue of RMB 6.506 billion, representing a year-on-year increase of 44.21%; profit attributable to owners of the parent company amounted to RMB 2.726 billion, marking a year-on-year increase of 111.47%; basic earnings per share were RMB 0.46; an interim dividend of HKD 20.1 cents per share is proposed.

The announcement stated that the Group's revenue mainly comes from the sales of pharmaceuticals. The Group’s key products are concentrated in its strategically focused major therapeutic areas, including oncology, anti-infectives, central nervous system disorders, metabolic and other diseases. The increase in revenue, profit, and basic earnings per share during the review period was primarily due to the rise in revenue from innovative drugs and collaborative products, attributed to increased sales of innovative drugs as well as upfront payments from collaboration partner GSK.